Table 2.

Univariate analysis of overall survival and local control probability.

	Outcomes at 6months (95% CI) and P-values
Factors	Overall survival		Local control
Age (years)
<50	85% (53–94)	0.69	60% (29–81)	0.60
≥50	82% (51–96)		53% (29–72)
Performance status
0–1	95% (68–99)	0.0261	76% (52–89)	<0.0011
2–4	61% (27–84)		14% (1–43)
Most recent histological diagnosis
WHO grade II–III	92% (54–99)	0.0161	64% (30–85)	0.21
WHO grade IV	78% (51–91)		52% (29–71)
Time from initial RT to progression
<600days	80% (51–93)	0.21	53% (29–72)	0.25
≥600days	86% (54–96)		61% (30–82)
Concurrent chemotherapy
Yes	68% (36–87)	0.20	38% (13–63)	0.24
No	94% (65–99)		68% (43–84)
Tumor morphological type
Diffuse	62% (28–84)	0.0061	21% (0.3–48)	<0.0011
Others	95% (68–99)		72% (49–87)
Contrast-enhancing tumor volume (cc)
<4cc	81% (51–93)	0.85	73% (46–88)	0.0181
≥4cc	86% (54–96)		33% (11–58)
Target delineation
Method A	73% (43–89)	0.084	47% (22–69)	0.0161
Method B	93% (61–99)		65% (38–82)

CI, confidence interval; RT, radiotherapy; WHO, World Health Organization.

¹Regarded as statistically significant (P<0.05).